eIF3a: A new anticancer drug target in the eIF family

Ji Ye Yin, Jian Ting Zhang, Wei Zhang, Hong Hao Zhou, Zhao Qian Liu

Research output: Contribution to journalShort survey

8 Scopus citations


eIF3a is the largest subunit of eIF3, which is a key player in all steps of translation initiation. During the past years, eIF3a is recognized as a proto-oncogene, which is an important discovery in this field. It is widely reported to be correlated with cancer occurrence, metastasis, prognosis, and therapeutic response. Recently, the mechanisms of eIF3a action in the carcinogenesis are unveiled gradually. A number of cellular, physiological, and pathological processes involving eIF3a are identified. Most importantly, it is emerging as a new potential drug target in the eIF family, and some small molecule inhibitors are being developed. Thus, we perform a critical review of recent advances in understanding eIF3a physiological and pathological functions, with specific focus on its role in cancer and anticancer drug targets.

Original languageEnglish (US)
Pages (from-to)81-87
Number of pages7
JournalCancer Letters
StatePublished - Jan 1 2018


  • Anticancer
  • Drug target
  • Translation initiation
  • Translation regulation
  • eIF3a

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'eIF3a: A new anticancer drug target in the eIF family'. Together they form a unique fingerprint.

  • Cite this

    Yin, J. Y., Zhang, J. T., Zhang, W., Zhou, H. H., & Liu, Z. Q. (2018). eIF3a: A new anticancer drug target in the eIF family. Cancer Letters, 412, 81-87. https://doi.org/10.1016/j.canlet.2017.09.055